Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial

Daryl Efron, Kaitlyn Taylor, Jonathan M Payne, Jeremy L Freeman, Noel Cranswick, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Katrina Williams, Daryl Efron, Kaitlyn Taylor, Jonathan M Payne, Jeremy L Freeman, Noel Cranswick, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Katrina Williams

Abstract

Introduction: Severe behavioural problems (SBPs) are a common contributor to morbidity and reduced quality of life in children with intellectual disability (ID). Current medication treatment for SBP is associated with a high risk of side effects. Innovative and safe interventions are urgently needed. Anecdotal reports and preliminary research suggest that medicinal cannabis may be effective in managing SBP in children with developmental disabilities. In particular, cannabidiol (CBD) may be a plausible and safe alternative to current medications. Families who are in urgent need of solutions are seeking cannabis for their ID children with SBP. However there is no evidence from randomised controlled trials to support the use of CBD for SBP. This pilot study aims to investigate the feasibility of conducting a randomised placebo-controlled trial of CBD to improve SBP in children with ID.

Methods and analysis: This is a single-site, double-blind, parallel-group, randomised, placebo-controlled pilot study of 10 participants comparing 98% CBD oil with placebo in reducing SBP in children aged 8-16 years with ID. Eligible participants will be randomised 1:1 to receive either CBD 20 mg/kg/day or placebo for 8 weeks. Data will be collected regarding the feasibility and acceptability of all study components, including recruitment, drop-out rate, study visit attendance, protocol adherence and the time burden of parent questionnaires. Safety outcomes and adverse events will be recorded. All data will be reported using descriptive statistics. These data will inform the design of a full scale randomised controlled trial to evaluate the efficacy of CBD in this patient group.

Ethics and dissemination: This protocol has received ethics approval from the Royal Children's Hospital ethics committee (Human Research Ethics Committee no. 38236). Results will be disseminated through peer-reviewed journals, professional networks, conferences and social media.

Trial registration number: ACTRN12618001852246.

Keywords: cannabidiol; children; intellectual disability; severe behavioural problems.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Leonard H, Petterson B, Bower C, et al. . Prevalence of intellectual disability in Western Australia. Paediatr Perinat Epidemiol 2003;17:58–67.10.1046/j.1365-3016.2003.00469.x
    1. Dekker MC, Koot HM, van der Ende J, et al. . Emotional and behavioral problems in children and adolescents with and without intellectual disability. J Child Psychol Psychiatry 2002;43:1087–98.10.1111/1469-7610.00235
    1. Hoare P, Harris M, Jackson P, et al. . A community survey of children with severe intellectual disability and their families: psychological adjustment, carer distress and the effect of respite care. J Intellect Disabil Res 1998;42:218–27.10.1046/j.1365-2788.1998.00134.x
    1. Willingham-Storr GL. Parental experiences of caring for a child with intellectual disabilities: a UK perspective. J Intellect Disabil 2014;18:146–58.10.1177/1744629514525132
    1. Llewellyn G, Dunn P, Fante M, et al. . Family factors influencing out-of-home placement decisions. J Intellect Disabil Res 1999;43:219–33.10.1046/j.1365-2788.1999.00189.x
    1. Doran CM, Einfeld SL, Madden RH, et al. . How much does intellectual disability really cost? first estimates for Australia. J Intellect Dev Disabil 2012;37:42–9.10.3109/13668250.2011.648609
    1. Einfeld SL, Ellis LA, Doran CM, et al. . Behavior problems increase costs of care of children with intellectual disabilities. J Ment Health Res Intellect Disabil 2010;3:202–9.10.1080/19315864.2010.524973
    1. Bhaumik S, Gangadharan S, Hiremath A, et al. . Psychological treatments in intellectual disability: the challenges of building a good evidence base. Br J Psychiatry 2011;198:428–30.10.1192/bjp.bp.110.085084
    1. Efron D, Danchin MH, Cranswick NE, et al. . Medication prescribed by Australian paediatricians: psychotropics predominate. J Paediatr Child Health 2017;53:957–62.10.1111/jpc.13615
    1. Einfeld SL. Systematic management approach to pharmacotherapy for people with learning disabilities. Adv psychiatr treat 2001;7:43–9.10.1192/apt.7.1.43
    1. Sheehan R, Horsfall L, Strydom A, et al. . Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open 2017;7:e01740610.1136/bmjopen-2017-017406
    1. Melville CA, Hamilton S, Hankey CR, et al. . The prevalence and determinants of obesity in adults with intellectual disabilities. Obes Rev 2007;8:223–30.10.1111/j.1467-789X.2006.00296.x
    1. Trollor J, Srasuebkul P, Xu H, et al. . Cause of death and potentially avoidable deaths in Australian adults with intellectual disability using retrospective linked data. BMJ Open 2017;7:e01348910.1136/bmjopen-2016-013489
    1. Klein DJ, Cottingham EM, Sorter M, et al. . A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072–9.10.1176/ajp.2006.163.12.2072
    1. Whiting PF, Wolff RF, Deshpande S, et al. . Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313:2456–73.10.1001/jama.2015.6358
    1. Robson P. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011;10:675–85.10.1517/14740338.2011.575778
    1. Epidiolex® prescribing information Greenwich Biosciences Inc; 2018.
    1. Devinsky O, Cilio MR, Cross H, et al. . Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791–802.10.1111/epi.12631
    1. Bergamaschi MM, Queiroz RHC, Zuardi AW, et al. . Safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Saf 2011;6:237–49.10.2174/157488611798280924
    1. Devinsky O, Marsh E, Friedman D, et al. . Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270–8.10.1016/S1474-4422(15)00379-8
    1. Devinsky O, Cross JH, Laux L, et al. . Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011–20.10.1056/NEJMoa1611618
    1. Rubin R. The path to the first FDA-approved cannabis-derived treatment and what comes next. JAMA 2018;320:1227–9.10.1001/jama.2018.11914
    1. Efron D, Freeman J. Medical cannabis for paediatric developmental-behavioural and psychiatric disorders. J Paediatr Child Health 2018;54:715–7.10.1111/jpc.13902
    1. Campbell CT, Phillips MS, Manasco K. Cannabinoids in pediatrics. J Pediatr Pharmacol Ther 2017;22:176–85.10.5863/1551-6776-22.3.176
    1. Földy C, Malenka RC, Südhof TC. Autism-Associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron 2013;78:498–509.10.1016/j.neuron.2013.02.036
    1. Jung K-M, Sepers M, Henstridge CM, et al. . Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 2012;3:108010.1038/ncomms2045
    1. Leweke FM, Piomelli D, Pahlisch F, et al. . Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e9410.1038/tp.2012.15
    1. Lim K, See YM, Lee J. A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci 2017;15:301–12.10.9758/cpn.2017.15.4.301
    1. Poleg S, Golubchik P, Offen D, et al. . Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry 2019;89:90–6.10.1016/j.pnpbp.2018.08.030
    1. Martin JH, Bonomo Y, Reynolds AD. Compassion and evidence in prescribing cannabinoids: a perspective from the Royal Australasian College of physicians. Med J Aust 2018;208:107–9.10.5694/mja17.01004
    1. Aman MG, Singh NN. Aberrant behavior checklist manual, second edition. East Aurora, NY: Slosson Educational Publications, Inc, 2017.
    1. Wechsler D, Hsiao-pin C. Wasi II: Wechsler abbreviated scale of intelligence. 2nd. Psychological Corporation, 2011.
    1. Hansson SL, Svanström Röjvall A, Rastam M, et al. . Psychiatric telephone interview with parents for screening of childhood autism - tics, attention-deficit hyperactivity disorder and other comorbidities (A-TAC): preliminary reliability and validity. Br J Psychiatry 2005;187:262–7.10.1192/bjp.187.3.262
    1. Larson T, Anckarsäter H, Gillberg C, et al. . The autism--tics, AD/HD and other comorbidities inventory (A-TAC): further validation of a telephone interview for epidemiological research. BMC Psychiatry 2010;10:110.1186/1471-244X-10-1
    1. Rutter M, Bailey A, Lord C. The social communication questionnaire: manual. Western Psychological Services, 2003.
    1. Guy GW, Robson PJ. A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of CBME per Oral in Healthy Male and Female Volunteers (GWPK0112). Journal of Cannabis Therapeutics 2004;3:79–120.10.1300/J175v03n04_01
    1. Guy W. Ecdeu assessment manual for psychopharmacology. US Department of Health, and Welfare, 1976: 534–7.
    1. Kurz R, Blaas K. Use of dronabinol (delta-9-thc) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids 2010;5:4–6.
    1. Kruger T, Christophersen E. An open label study of the use of dronabinol (marinol) in the management of treatment-resistant self-injurious behavior in 10 retarded adolescent patients. J Dev Behav Pediatr 2006;27:433.10.1097/00004703-200610000-00029
    1. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 2015;45:49–52.10.1016/j.yebeh.2015.02.043
    1. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013;29:574–7.10.1016/j.yebeh.2013.08.037
    1. Barchel D, Stolar O, De-Haan T, et al. . Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol 2018;9:152110.3389/fphar.2018.01521
    1. Aran A, Cassuto H, Lubotzky A, et al. . Brief report: Cannabidiol-Rich cannabis in children with autism spectrum disorder and severe behavioral Problems-A retrospective feasibility study. J Autism Dev Disord 2019;49:1284–8.10.1007/s10803-018-3808-2
    1. Bar-Lev Schleider L, Mechoulam R, Saban N, et al. . Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 2019;9:20010.1038/s41598-018-37570-y
    1. Bedell G. Further validation of the child and adolescent scale of participation (CASP). Dev Neurorehabil 2009;12:342–51.10.3109/17518420903087277
    1. Stevens K. Valuation of the child health utility 9D index. Pharmacoeconomics 2012;30:729–47.10.2165/11599120-000000000-00000
    1. Stevens K. Developing a descriptive system for a new preference-based measure of health-related quality of life for children. Qual Life Res 2009;18:1105–13.10.1007/s11136-009-9524-9
    1. Bruni O, Ottaviano S, Guidetti V, et al. . The sleep disturbance scale for children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. J Sleep Res 1996;5:251–61.10.1111/j.1365-2869.1996.00251.x
    1. Richardson J, Iezzi A, Khan MA, et al. . Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument. Patient 2014;7:85–96.10.1007/s40271-013-0036-x
    1. Hoffman L, Marquis J, Poston D, et al. . Assessing family outcomes: psychometric evaluation of the beach center family quality of life scale. J Marriage Fam 2006;68:1069–83.10.1111/j.1741-3737.2006.00314.x
    1. Lovibond SH, Lovibond PF. Manual for the depression anxiety stress scales. Psychology Foundation of Australia, 1996.
    1. Silva LMT, Schalock M. Autism parenting stress index: initial psychometric evidence. J Autism Dev Disord 2012;42:566–74.10.1007/s10803-011-1274-1

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться